Min Yuen Teo 張鳴元

MSKCC GU Medical Oncologist with focus on #bladdercancer and #prostatecancer. Views are my own.

[Toni Choueiri, MD @DrChoueiri]

Congrats to the whole team @DanaFarber_GU on this new @AACR paper in Molecular Cancer Research

This is the result of over 4+ years of work with 3 labs @DanaFarber, where @adib_elio @AminNassarMD @sarahaboualaiwi were residents/fellows @BrighamMedRes @YaleCancer and @SylvanBacaLab was a post-doc!

Thank you @MichelleDunno17 @SashaGusevPosts @mouwlab for being the best collaborators!

Link: https://t.co/JPi9QZQzuX

[Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) @TiansterZhang]

@CaPsurvivorship @DanaFarber_GU reports her many year #ARACOG trial — important objective measures for cognitive changes on darolutamide vs enzalutamide in #prostatecancer. Daro w improved cog fxn vs enza. Important work for ARPI selection. @asco #ASCO26 @oncoalert @urotoday

[QianJanieQin @QianJanieQin]

#COMPPARE early results: in localized #ProstateCancer, #proton therapy vs #IMRT showed no sig difference in pt-reported bowel urgency/frequency, ≥G2 GI toxicity, or 3-year biochemical control. Longer follow-up needed for late toxicity/long term outcomes #ASCO2026

[Adam B. Weiner, MD @Adam_Weiner535]

🚨 PROTEUS: perioperative apalutamide moves into high-risk localized #prostatecancer

Just out in @NEJM

🧬 2109 men w/ high-risk localized or locally advanced PCa randomized to ADT + apalutamide vs ADT + placebo around radical prostatectomy.

🎯 Both stated primary endpoints met.

⚠️ But the trial deserves nuance. Thread 🧵

#ASCO26 @ASCO @PCF_Science

[Tom Powles @tompowles1]

Clear cell RCC sheds low levels of ctDNA, but positivity and ctDNA dynamics are relevant in the adjuvant setting @DrChoueiri #ASCO26. This analysis is with an exome based personalised technique and shows a lack of sensitivity (5-8% ctDNA+ve rate vs 40% radiological relapse rate) but good specificity (almost all ctDNA +ves relapse). Whole genome ctDNA analysis should work work better. There is a future for ctDNA in renal cancer, we’re just not quite there yet IMO.

[Entisar saleh @Entisar_kilani]

Metastatic prostate cancer ESMO guidelines .

#oncology #ESMO #medtwitter

[Samuel Hume @DrSamuelBHume]

How modern therapies dislodged chemotherapy in advanced urothelial carcinoma

[Oscar Tahuahua @OscarTahuahua]

Retrospective real-world clinicogenomic study in @Nature

5893 pts with mCRPC
37% HRR pathogenic variants.
13% BRCA1/2.

389 received olaparib:

BRCA2: median OS 17.5 mo
BRCA1: 8.1 mo
HR 2.23 (P=0.008)
BRCA1 clearly worse.

Within BRCA2, subtype defines benefit ⚠️

BRCA2 loss: median OS 24.3 mo
HR 0.42 (P<0.001)

This is intra-BRCA functional heterogeneity ‼️

Not all BRCA alterations are biologically or therapeutically equivalent.
https://t.co/EVyVPFf7HN @OncoAlert

[Toni Choueiri, MD @DrChoueiri]

This is a massively important trial —you rarely see this. Important for the field and for the region. It's time to reflect on PD1 dosing… !

Bravo @VanitaNoronha et al!

@OncoAlert @JCO_ASCO @TataMemorial @ASCO

[JAMA Oncology @JAMAOnc]

Pembrolizumab combined with platinum-based chemotherapy showed a 39.4% response rate and manageable toxicity as a potential first-line treatment for advanced penile squamous cell carcinoma.

https://t.co/A5unScwF2i

[Toni Choueiri, MD @DrChoueiri]

JUST IN: 2 Belzutifan (HIF2 inhibitor) phase III trials POSTIVE for Primary Endpoint in Renal Cell Carcinoma: LITEPSPAK022 (adjuvant) + LITESPARK011 (metastatic, post PD1).

BIG NEWS for GU Oncology + Kidney Cancer patients!

https://t.co/poOKpXP5nJ
https://t.co/wP9gu8ppLI

[Tom Powles @tompowles1]

2/2 this becomes standard of care here. Questions-How would this perform in a cisplatin eligible population? Better? Can ctDNA help? How many cycles are needed? B15 &amp; VOLGA can help here.Finally, bladder sparing trials are needed to address the need for surgery @OncoAlert #ESMO25

[Tom Powles @tompowles1]

1/2 KN905 Enfortumab Vedotin + Pembro continues to transform bladder cancer in spectacle fashion. In cisplatin ineligible operable disease it beats cystectomy with EFS HR 0.4, OS HR 0.5. pCR of 57% is much ⬆️ than anything before #ESMO25 pCR&gt; 50% questions unselected surgery

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Wonderful talk by @PGrivasMDPhD on neoadj #bladdercancer treatment w updates #NIAGARA , role of ctDNA and ongoing neoadjuvant/adjuvant trials👉his take home message for our clinical practice.
#ESMO25 #ESMOAmbassador @OncoAlert @myESMO

[Elizabeth Plimack MD @ERPlimackMD]

The bar is raised! Periop 🥪 EVP for cis ineligible (90%) or refusing (10%) MIBC = new SOC *KN905/EV302*
✅pT0 rate highest ever in MIBC 57% ITT, 65% cystectomy sub-pop
✅2yr EFS &amp; OS on par w DDMVAC in cis eligible
-cis eligible EVP🥪 trial *KNB15/EV304* readout awaited #ESMO25

[Tom Powles @tompowles1]

Renal cancer 1st line randomised PII KMUA3B #ESMO25 with lenavatinib/pembro as the control (hard to beat with RR&gt;80%). Len/pem/belzutifan showed good PFS (HR0.45) ✅ which may lead to a positive RIII (LS12) which is ongoing. TIGIT 🛑 &amp; LAG3 🛑 were disappointing again @OncoAlert

[David H Aggen, MD PhD @Dr_Aggen]

🚨 New data at #ESMO25!
Outcomes with enfortumab vedotin + pembrolizumab (EV/P) in metastatic urothelial carcinoma harboring FGFR3 or ERBB2 alterations.

Presented by @MichalSternsch & @dr_aggen — Poster #3102P

📍Memorial Sloan Kettering Cancer Center | #MSKCC | @@MSK_DeptofMed
#BladderCancer #Oncology

[Tom Powles @tompowles1]

RAMPART #ESMO25 adjuvant durvalumab/tremelimumab delays DFS in adjuvant RCC vs supportive care. This is confusing as ipi/nivo did not hit DFS. Durvalumab monotherapy data will help on component parts. Benefit seems confined to good risk. Adjuvant pembro has OS here. @OncoAlert

[European Urology @EUplatinum]

#RenalCancer #Epidemiology Update:
#Incidence, #Mortality, #Survival, #GeneticPredisposition, and #RiskFactors

• 🌍 434,840 cases and 11,953 deaths in 2022
• 📈 Incidence projected to increase by +72% by 2050
• 📈 Mortality projected to increase by +96% by 2050
• 📊 5-year survival: 66–75%
• 🧬 Specific genetic background and hereditary renal cancer syndromes
• 🎯 Review of modifiable and non-modifiable risk factors

@_alelarcher @Ric_Campi @FreddieBray_ @LauraBukavinaMD @EJonasch @AhJemal @LauraMarandino @vmollica7 @KidneyCancerDoc @grantissimus @MaxineGBTran @uretericbud

👉 https://t.co/y1GktT7Nzw

[European Urology @EUplatinum]

🚨 New in European Urology:
Consolidative surgery after #EnfortumabVedotin +/– ICI in advanced urothelial carcinoma:
✅ 82% downstaging
✅ 43% ypT0N0
✅ 79% stopped systemic therapy
✅ 89% DFS in curative group

📄 https://t.co/Yd52YZKRNk
#BladderCancer #Immunotherapy #Urology